|1.||Frézard, Frédéric: 11 articles (10/2014 - 01/2004)|
|2.||Demicheli, Cynthia: 9 articles (10/2014 - 01/2004)|
|3.||Khamesipour, Ali: 9 articles (09/2014 - 01/2005)|
|4.||Schubach, Armando de Oliveira: 6 articles (01/2015 - 05/2005)|
|5.||Mohebali, M: 6 articles (02/2012 - 07/2007)|
|6.||Layegh, Pouran: 5 articles (12/2015 - 07/2007)|
|7.||Ribeiro, Raul R: 5 articles (10/2014 - 06/2006)|
|8.||Khatami, Alireza: 5 articles (01/2014 - 01/2005)|
|9.||Firooz, Alireza: 5 articles (01/2013 - 01/2005)|
|10.||Moghiman, Toktam: 4 articles (12/2015 - 07/2007)|
07/01/2009 - "Glucantime is still effective against Old World cutaneous leishmaniasis when used in the doses recommended by WHO."
11/01/2012 - "Meglumine antimoniate compounds have been the mainstay of treatment for cutaneous leishmaniasis (CL) for decades. "
01/01/2012 - "amazonensis model, intralesional treatment with MI-4-OCH(3) or MI-4-NO(2) showed greater therapeutic efficacy than treatment with meglumine antimoniate, and the new topical formulations of these compounds also displayed great activity in the cutaneous leishmaniasis model. "
01/01/2008 - "The objective of this study was to compare the clinical efficacy of intramuscular pentavalent antimonial compound meglumine antimoniate alone and in combination with intralesional therapy in the treatment of Old World cutaneous leishmaniasis. "
04/01/2013 - "Glucantime remains the first-line treatment for cutaneous leishmaniasis. "
02/01/2002 - "Results from a study are reported in which patients with leishmaniasis were monitored by whole blood, blood plasma, urine, and hair analysis, before, during, and after intramuscular administration of N-methyl meglumine antimoniate. "
03/01/2015 - "major to glucantime were evaluated with amastigote macrophage and mice model of leishmaniasis. "
03/01/2014 - "These results indicate that GALMAN-A is three times more potent and its oxovanadium complex is twelve times more potent than Glucantime (300μg/ml), which is the drug of choice in leishmaniasis treatment. "
01/01/2014 - "The conventional treatment for tegumentary leishmaniasis is meglumine antimoniate, which needs parenteral administration, has increased therapeutic failure, and produces serious adverse effects, justifying the search for therapeutic alternatives. "
08/01/2013 - "Pentavalent antimonials such as meglumine antimoniate (MA) are the primary treatments for leishmaniasis, a complex disease caused by protozoan parasites of the genus Leishmania . "
|3.||Visceral Leishmaniasis (Kala Azar)
06/01/1962 - "[8 cases of kala-azar cured with glucantime]."
08/01/2007 - "The present study aimed to evaluate the renal and hepatic responses in eight dogs with visceral leishmaniasis submitted to treatment with meglumine antimoniate and to verify the occurrence of possible side effects. "
04/01/1997 - "In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis."
01/01/2015 - "Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil."
06/01/2012 - "An innovative liposomal formulation of meglumine antimoniate (LMA) was recently reported to promote both long-term parasite suppression and reduction of infectivity to sand flies in dogs with visceral leishmaniasis. "
07/01/2015 - "All compounds tested showed selectivity indexes higher than that of the reference drug glucantime for the three Leishmania species, and the less bulky monoalkylamino substituted derivatives 2 and 4 were clearly more effective than their bisalkylamino substituted counterparts 1 and 3. Both infection rate measures and ultrastructural alterations studies confirmed that 2 and 4 were highly leishmanicidal and induced extensive parasite cell damage. "
06/01/2013 - "In vitro analysis regarding the safety of components used in a film-based therapeutic system loaded with meglumine antimoniate and its activity toward Leishmania major experimental infections: a preliminary study."
07/01/2014 - "Compounds 1-4 were more active and less toxic than glucantime and both infection rates and ultrastructural alterations confirmed that 1 and 2 were highly leishmanicidal and induced extensive parasite cell damage. "
01/01/2014 - "Sixteen macrophage drug-response genes were modulated by infection and exposure to meglumine antimoniate. "
04/01/2013 - "Twenty-eight dogs with clinical disease due to natural infection with Leishmania infantum were treated with 75 mg/kg meglumine antimoniate SC every 12h for 60 days. "
04/01/2012 - "Decreasing the scar size and the low cost are two promising aspects in introducing 5% TCA cream as a potential alternative for intralesional glucantime in the treatment of CL. "
07/01/1995 - "All patients reacted favorably to treatment with glucantime, with lesion scarring. "
12/01/2015 - "The results of the present study showed that application of nanochitosan film increased the wound contraction rate, reepithelialization rate, and scar tissue formation, and its combination with glucantime significantly reduced lesion size and parasite loads. "
04/01/1990 - "Our data represent evidence for the reversibility of the abnormal HLA-DR expression by keratinocytes in ACL after Glucantime therapy or spontaneous scar formation, demonstrating that this expression is restricted to the period of active lesions. "
06/01/2013 - "To control the characteristic skin ulcers of cutaneous leishmaniasis (CL), the use of a biopolymeric system that favors the scar healing process and releases an active agent such as meglumine antimoniate may be a better option. "
|3.||Paromomycin (Paromomycin Sulfate)
|5.||Antimony Sodium Gluconate (Sodium, Stibogluconate)
|2.||Cryotherapy (Therapy, Cold)
|5.||Drug Therapy (Chemotherapy)